Age-adjusted CSF t-tau and NfL do not improve diagnostic accuracy for prodromal Alzheimer's disease

被引:0
|
作者
Knudtzon, Stephanie Lindgard [1 ,2 ]
Nordengen, Kaja [3 ,4 ]
Grontvedt, Goril Rolfseng [5 ,6 ]
Jarholm, Jonas [3 ,4 ]
Eliassen, Ingvild Vollo [3 ,7 ]
Selnes, Per [3 ]
Palhaugen, Lene [3 ,4 ]
Espenes, Jacob [1 ,2 ]
Gisladottir, Berglind [3 ,8 ,9 ]
Waterloo, Knut [1 ,2 ]
Fladby, Tormod [3 ,4 ]
Kirsebom, Bjorn-Eivind [1 ,2 ]
机构
[1] Univ Hosp North Norway, Dept Neurol, N-9038 Tromso, Norway
[2] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Psychol, Tromso, Norway
[3] Akershus Univ Hosp, Dept Neurol, Lorenskog, Norway
[4] Univ Oslo, Inst Clin Med, Oslo, Norway
[5] Norwegian Univ Sci & Technol, Fac Med & Hlth Sci, Dept Neuromed & Movement Sci, Trondheim, Norway
[6] Univ Hosp Trondheim, Dept Neurol & Clin Neurophysiol, Trondheim, Norway
[7] Univ Oslo, Dept Psychol, Oslo, Norway
[8] Akershus Univ Hosp, Med Div, Clin Mol Biol EpiGen, Oslo, Norway
[9] Univ Oslo, Oslo, Norway
关键词
Alzheimer's disease; aging; neurofilament light chain; normative reference data; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID TAU; BIOMARKERS; DEMENTIA; PROGRESSION; PATHOLOGY; PROTEINS; MARKERS; PREDICT; IMPACT;
D O I
10.1016/j.neurobiolaging.2024.05.016
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Cerebrospinal fluid total -tau (t -tau) and neurofilament light chain (NfL) are biomarkers of neurodegeneration and are increased in Alzheimer's disease (AD). In order to adjust for age -related increases in t -tau and NfL, crosssectional age -adjusted norms were developed based on amyloid negative cognitively normal (CN) adults aged 41-78 years (CN, n = 137). The age -adjusted norms for t -tau and NfL did not improve receiver operating curve based diagnostic accuracies in individuals with mild cognitive impairment (MCI) due to AD (AD -MCI, n = 144). Furthermore, while NfL was correlated with higher age in AD -MCI, no significant correlation was found for t -tau. The cox proportional hazard models, applied in 429 participants with baseline t -tau and NfL, showed higher hazard ratio of progression to MCI or dementia without age -adjustments (HR = 3.39 for t -tau and HR = 3.17 for NfL), as compared to using our norms (HR = 2.29 for t -tau and HR = 1.89 for NfL). Our results indicate that utilizing normative reference data could obscure significant age -related increases in these markers associated with neurodegeneration and AD leading to a potential loss of overall diagnostic accuracy.
引用
收藏
页码:74 / 84
页数:11
相关论文
共 44 条
  • [1] CSF sTREM2 in deliriumrelation to Alzheimer's disease CSF biomarkers Aβ42, t-tau and p-tau
    Henjum, Kristi
    Quist-Paulsen, Else
    Zetterberg, Henrik
    Blennow, Kaj
    Nilsson, Lars N. G.
    Watne, Leiv Otto
    JOURNAL OF NEUROINFLAMMATION, 2018, 15
  • [2] CSF in Epileptic Prodromal Alzheimer's Disease: No Diagnostic Contribution but a Pathophysiological One
    Cretin, Benjamin
    Bousiges, Olivier
    Hautecloque, Geoffroy
    Philippi, Nathalie
    Blanc, Frederic
    Dibitonto, Laure
    Martin-Hunyadi, Catherine
    Sellal, Francois
    FRONTIERS IN NEUROLOGY, 2021, 12
  • [3] CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
    Kristi Henjum
    Else Quist-Paulsen
    Henrik Zetterberg
    Kaj Blennow
    Lars N. G. Nilsson
    Leiv Otto Watne
    Journal of Neuroinflammation, 15
  • [4] Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ42 and T-Tau assays for Alzheimer's disease diagnosis
    Bayart, Jean-Louis
    Hanseeuw, Bernard
    Ivanoiu, Adrian
    van Pesch, Vincent
    JOURNAL OF NEUROLOGY, 2019, 266 (09) : 2304 - 2311
  • [5] Interest of CSF β-amyloid1-42 and t-tau protein level determinations for the diagnosis of Alzheimer's disease
    Smach, M. A.
    Charfeddine, B.
    Lammouchi, T.
    Drid, H.
    Ben Othman, L.
    Bennamou, S.
    Limem, K.
    ANNALES DE BIOLOGIE CLINIQUE, 2008, 66 (05) : 531 - 535
  • [6] Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
    Mattsson, Niklas
    Smith, Ruben
    Strandberg, Olof
    Palmqvist, Sebastian
    Scholl, Michael
    Insel, Philip S.
    Hagerstrom, Douglas
    Ohlsson, Tomas
    Zetterberg, Henrik
    Blennow, Kaj
    Jogi, Jonas
    Hansson, Oskar
    NEUROLOGY, 2018, 90 (05) : E388 - +
  • [7] 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease
    Mattsson, Niklas
    Scholl, Michael
    Strandberg, Olof
    Smith, Ruben
    Palmqvist, Sebastian
    Insel, Philip S.
    Hgerstrom, Douglas
    Ohlsson, Tomas
    Zetterberg, Henrik
    Jogi, Jonas
    Blennow, Kaj
    Hansson, Oskar
    EMBO MOLECULAR MEDICINE, 2017, 9 (09) : 1212 - 1223
  • [8] Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays
    van Harten, Argonde C.
    Wiste, Heather J.
    Weigand, Stephen D.
    Mielke, Michelle M.
    Kremers, Walter K.
    Eichenlaub, Udo
    Dyer, Roy B.
    Algeciras-Schimnich, Alicia
    Knopman, David S.
    Jack Jr, Clifford R.
    Petersen, Ronald C.
    ALZHEIMERS & DEMENTIA, 2022, 18 (04) : 635 - 644
  • [9] Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ42 using Meso Scale Discovery Assays for Alzheimer's Disease
    Pan, Catherine
    Korff, Ane
    Galasko, Douglas
    Ginghina, Carmen
    Peskind, Elaine
    Li, Ge
    Quinn, Joseph
    Montine, Thomas J.
    Cain, Kevin
    Shi, Min
    Zhang, Jing
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 45 (03) : 709 - 719
  • [10] CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease
    Toledo, Jon B.
    Korff, Ane
    Shaw, Leslie M.
    Trojanowski, John Q.
    Zhang, Jing
    ACTA NEUROPATHOLOGICA, 2013, 126 (05) : 683 - 697